ecancer

iManageCancer: System design and integration

Stephan Kiefer – Fraunhofer Institut Biomedizinische Technik, Sankt Ingbert, Germany

15 Feb 2016

iManageCancer: the Health Avatar Personal Health Record

Prof Feng Dong - University of Bedfordshire, Luton, UK

15 Feb 2016

Editor's choice for January 2016

Prof Gordon McVie - ecancer Editor

2 Feb 2016

Utilising disease heterogeneity and emerging biomarkers to individualise prostate treatment

Dr Bertrand Tombal – Saint-Luc Hospital, Brussels, Belgium

22 Jan 2016

The ManVan: a mobile cancer support service for men with prostate, testicular and penile cancer in Wales

Dr Rachel Iredale -Tenovus Cancer Care, Cardiff, Wales, UK and University of South Wales, Pontypridd, Wales, UK

11 Jan 2016

Entinostat and high-dose Interleukin 2 in renal cell carcinoma patients

Prof Roberto Pili - Indiana University, Indianapolis, USA

9 Jan 2016

Gemcitabine plus cisplatin plus ipilimumab for metastatic urothelial cancer

Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA

8 Jan 2016

Avelumab for metastatic urothelial carcinoma: JAVELIN trial

Dr Andrea Apolo - National Cancer Institute, Maryland, USA

8 Jan 2016

Subgroup analyses of METEOR; randomized phase III trial of cabozantinib vs everolimus for RCC

Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France

8 Jan 2016

Integrated genomic correlates of response to PD-1 inhibitor nivolumab in mRCC

Dr Guillermo de Velasco - Dana-Farber Cancer Institute, Boston, USA

8 Jan 2016

Discontinuing VEGF-targeted therapy for progression or toxicity affects outcomes of second-line therapies in mRCC

Dr Guillermo de Velasco - Dana-Farber Cancer Institute, Boston, USA

8 Jan 2016

Impact of metformin on outcomes for metastatic renal cell carcinoma

Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA

8 Jan 2016

More from ecancer